Pulmonary hypertension is common in children with Trisomy 21, frequently with multifactorial aetiologies. Registry data provide better understanding of disease development, diagnostic workup and treatment patterns in children with Trisomy 21. TOPP (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) is a centre-based, comprehensive registry.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious disease caused by persistent thromboembolic obstruction or narrowing of the pulmonary arteries. Its prevalence varies, and many cases remain undiagnosed, contributing to a substantial clinical burden.
Part of the 'Hypoxia in pulmonary vascular research – altitude and beyond' webinar series by the High Altitude Task Force, who raise awareness and understanding of PH linked to high altitude and organise scientific conferences in regions affected by high altitudes.
Pulmonary emboli (PE) are a common clinical problem seen when a peripheral deep vein thrombosis (DVT) migrates to the pulmonary arteries. However, emerging literature suggests that not all filling defects in the pulmonary arteries are the result of embolism, and that in situ pulmonary arterial thrombus (ISPAT) or low-flow stasis artifact (LFSA) within the pulmonary arteries can mimic acute PE.
Pediatric pulmonary arterial hypertension (PAH) has a long asymptomatic period with progressive vascular loss. A recent computational model of simulated PAH in humans has demonstrated that up to 70% of the pulmonary vasculature is lost before clinical PAH criteria are met.
Pulmonary endarterectomy (PEA) is the gold standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH). While balloon pulmonary angioplasty (BPA) is an emerging treatment for distal CTEPH, a standard therapeutic strategy for CTEPH with unilateral central lesions has yet to be established.
Renal impairment is considered a contra-indication for lung (LTX) or combined heart-lung (HLTX) transplantation due to increased mortality. We hypothesized that renal impairment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is the result of reduced cardiac output and should be partly reversible after LTX.
To analyse the clinical characteristics and potential pregnancy outcomes of deceased pregnant women with pulmonary hypertension, we conducted a retrospective analysis of clinical data from 54 cases of pregnant women with pulmonary hypertension at The Third Affiliated Hospital of Guangzhou Medical University from May 2009 to February 2022.
'Pulmonary Hypertension in the Shadow of Infections: Challenges in Indian Practice' is part of the Virtual Symposium Series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
